On January 5, 2019 NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases reported that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California (Press release, NantKwest, JAN 5, 2019, View Source [SID1234532486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NantKwest will be sharing with analysts and investors a review of the company’s activities in 2018 and provide an overview for 2019.

At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide a roadmap for the company’s clinical programs for 2019.

The event will begin at 7:00 PM PT on Tuesday, January 8, 2019 and is expected to conclude at 9:00 PM PT. A replay of the presentation will be posted on the NantKwest website and will be available for 30 days following the event